Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
2019 · Nature · 282 citations
https://doi.org/10.1038/s41586-019-1347-4
X
Xiaoju Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
144
Papers
6.9K
Citations
28
h-index
41
i10-index
Xiaoju Wang is an academic researcher from Michigan Center for Translational Pathology. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Epigenetics and DNA Methylation & Cancer-related molecular mechanisms research. The author has an h-index of 28, co-authored 123 publications.
ORCID: 0000-0002-1800-4902Papers by this author
worksSub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy
2019 · EBioMedicine · 163 citations
https://doi.org/10.1016/j.ebiom.2019.05.023
WBSCR22 confers oxaliplatin resistance in human colorectal cancer
2017 · Scientific Reports · 49 citations
https://doi.org/10.1038/s41598-017-15749-z
Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer
2017 · Scientific Reports · 30 citations
https://doi.org/10.1038/srep40786
Doxorubicin Inhibits Proliferation of Osteosarcoma Cells Through Upregulation of the Notch Signaling Pathway
2015 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 24 citations
https://doi.org/10.3727/096504015x14343704124340
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
2024 · Cell Reports Medicine · 24 citations
https://doi.org/10.1016/j.xcrm.2024.101758
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat